In another example of a joint U.S.-Israel partnership, leading medical research institutions in each country are teaming up to develop and market new technologies in the area of nanotechnology, the manipulation of matter on an atomic, molecular, and supramolecular scale.
The Hebrew University of Jerusalem and the Cleveland Clinic announced last week the establishment of a virtual global Center for Transformative Nanomedicine. The partnership, with an initial five-year commitment to raise $15 million will sponsor research in cardiovascular disease, neurological disease and cancer.
The project’s goal is new drug delivery systems and new medical technologies.
“Our two institutions will leverage resources and begin to combine our scientific knowledge,” said Menahem Ben Sasson, president of Hebrew University. “These powerful interactions will expedite better medical treatments, more rapid, cost-effective diagnostics, and improved healthcare delivery for people the world over.”
Nanotechnology enables physicians to deliver calibrated doses of medications to select sites in the body, and release them there, reducing side effects and damages to other sites.
Research will take place at Hebrew University’s Faculty of Medicine and School of Pharmacy and other parts of the university, and Cleveland Clinic’s Lerner Research Institute and Department of Biomedical Engineering.
S.L.
